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Abstract
Background: Epidemiological studies suggest that compared with the general population, mood disorders are up
to 4.7 times more prevalent in substance dependent samples. Comorbid substance use disorder (SUD) and
depression has been associated with a more severe and protracted illness course and poorer treatment outcomes.
Despite this, the development and assessment of behavioural interventions for treating depression among
individuals with SUDs have received little empirical attention. Behavioural Activation Treatment for Depression
(BATD-R) is an empirically supported treatment for depression that has shown some efficacy among substance
users. This paper describes the study protocol of a parallel, single blind, randomised controlled trial to determine
the efficacy and feasibility of a modified version of the BATD-R (Activate) in reducing symptoms of depression and
substance dependence among individuals in residential rehabilitation (RR) and opioid substitution therapy (OST).
Methods/design: A sample of approximately 200 individuals with depressive symptomatology in treatment
for SUD will be recruited from RR and OST services in New South Wales, Australia. Dynamic random allocation
following minimisation methodology will be used to assign participants to one of two groups. The control group
will receive treatment as usual (TAU), which will be the model of care provided in accordance with standard
practice at participating RR and OST services. The intervention group will receive Activate, comprising 10 individual
60-min therapy sessions with a psychologist employed on the research team, in addition to TAU. Data collection
will occur at baseline (pre-intervention), and 3-months and 12-months post baseline.
Discussion: The association between depression and substance dependence has been well documented, yet
practical and effective treatments are scarce. The findings of the present study will contribute significantly to
understanding the types of programs that are effective in treating this comorbidity.
Trial registration: This trial is registered with the Australian and New Zealand Clinical Trials registry,
ACTRN12613000876796. Registered on 7 August, 2013.
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Background
The frequent co-occurrence of depression and substance
use disorders (SUDs) is well documented both in Australia
and internationally [1–9], with epidemiological studies
suggesting that affective disorders are up to 4.7 times
more prevalent among substance dependent samples
compared to the general population [10–12]. Particular
cause for concern is the high prevalence of current major
depression among treatment seeking substance users, with
studies reporting rates as high as 20–55 % [2, 4, 13–15].
Despite evidence that depression is linked to poorer treat-
ment outcomes [16–20], the development and assessment
of behavioural interventions for depression among sub-
stance users has received little empirical attention.
Impact of depression on treatment for drug dependence
Among substance users, depression has been associated
with a more severe and protracted illness course, poorer
social and occupational functioning, greater use of health
services, an increased risk of post-traumatic stress dis-
order, higher risk of suicidal behaviours, and an increased
risk of relapse in substance use problems [20–22]. The
Australian Treatment Outcome Study (ATOS), a longitu-
dinal study of treatment outcomes for heroin dependence,
demonstrated that across a 3 year follow-up period clients
who met DSM-IV criteria for major depression in the
month preceding interview were more likely to be using
heroin and other drugs, to be heroin-dependent, sharing
needles, experiencing injection-related health problems,
engaging in crime and were in poorer physical and mental
health than non-depressed clients [20]. Depression was
the only consistent predictor of poorer treatment out-
come across the 3 year period [20]. Clearly, co-occurring
depression and SUDs presents a complex clinical chal-
lenge for treatment providers that requires further empi-
rical attention.
Depression and SUDs, when considered as separately
occurring disorders, can be attributed to a number of
environmental, genetic and neurobiological factors. In
contrast, the mechanisms underlying these conditions as
they co-occur are not well understood [23]. Four main
hypotheses have been proposed to explain this comor-
bidity [24]. The self-medication hypothesis suggests that
substance dependence occurs as a result of repeated sub-
stance use aimed at relieving the symptoms of depression.
Secondly, depressive symptoms may develop as a direct
result of taking substances or as part of withdrawal symp-
toms when substance use stops (e.g. substance-induced
depression). Thirdly, depressive symptoms may develop in
response to the lifestyle associated with using substances.
Alternatively, both disorders may share common psycho-
logical or biological antecedents, thereby increasing the
likelihood that they will co-occur. Regardless of which dis-
order came first, once co-occurring SUD and depression
has been established, each may act to maintain or exacer-
bate the other [24].
Current treatment protocols for co-occurring depression
and SUDs
While treatment has traditionally been determined based
on the temporal relationship between depression and
SUDs (i.e., treating the disorder with the earlier onset
first), there are practical difficulties in reliably diagnosing
primary and secondary conditions [25]. It has been
suggested that the primary/secondary distinction is imma-
terial once depression and SUDs have surfaced [26], and
that the focus of treatment should be on the impairment
and distress caused by symptoms, as opposed to diagnos-
tic sub-type classification, or the model of aetiology [27].
There is some evidence, albeit limited, for the effec-
tiveness of cognitive behavioural therapy (CBT) either
alone or in combination with antidepressant use for the
treatment of co-occurring depression and SUDs [28].
Unfortunately, however, only a handful of methodolo-
gically sound studies have been conducted to date, and
these have focused on alcohol use outcomes, with
limited reports on other substance use outcomes. While
there is support for the use of CBT in the treatment of
depression and co-occurring tobacco [29] and alcohol
dependence [30], there are a number of difficulties when
implementing depression focussed CBT treatment in a
population dependent on a variety of licit and illicit
substances, as outlined by Daughters and colleagues
[31]. CBT focuses on complex cognitive techniques,
which may be too cognitively challenging for chronic
substance users with cognitive deficits and low educa-
tion levels [32, 33]. Its time-consuming nature makes it
difficult to incorporate into existing substance abuse
treatments [34] and it requires a high level of training in
complex therapy based treatments, which staff may not
be able to deliver in traditional drug and alcohol treat-
ment settings [35].
Behavioural activation
A treatment that may be better suited for use among
substance users is behavioural activation. According to
this approach, symptoms and behaviours characteristic of
depression arise when susceptible people experience
problems that significantly reduce their ability to gain
positive reward from their environment [36]. Behavioural
activation is a structured treatment for depression de-
signed to activate clients in ways that are tailored to
increase rewarding experiences in their lives [36]. It is an
action oriented approach that requires between session
practice by clients, with therapists and clients working
collaboratively to develop activation tasks for clients to
complete outside the session and trouble-shoot obstacles
that may arise. Empirical evidence suggests that behavioural
Ross et al. BMC Psychiatry  (2016) 16:221 Page 2 of 14
activation therapy is just as effective as CBT [37, 38], and is
more time efficient and less complex when compared to
most other treatments for depression [39]. Behavioural acti-
vation therapy has been shown to be an efficacious, cost-
effective alternative to cognitive therapy and antidepressant
medication [40, 41].
Behavioural Activation Treatment for Depression
(BATD) [39] is a brief manualised treatment which
employs activity scheduling and other behavioural tech-
niques within a framework applying matching law [42]
to understand depression. This law suggests that depres-
sion persists when (a) reinforcement available for non-
depressed (healthy) behaviour is low or non-existent, or
(b) depressed (unhealthy) behaviour provides a relatively
high degree of reinforcement [39]. Depression is there-
fore seen as the result of both decreased reinforcement
for non-depressed, healthy behaviours, and increased
reinforcement for depressed behaviours [43]. The struc-
tured BATD protocol seeks to increase non-depressed
behaviour by providing exposure to the positive conse-
quences of healthy behaviour, and has shown promise in
treating depression among substance users [31, 44]. The
manual was recently revised ([BATD-R; [45]), to improve
delivery and patient acceptability.
Evidence base for BATD
Lead developers of the manual, Lejeuz and Hopko, first
pilot tested BATD among psychiatric inpatients suffering
depression, and yielded a large pre-to-post treatment
effect size (d = .73) for depression symptoms [46]. BATD
gained additional support from three small randomised
controlled pilot trials [31, 44, 47]. Daughters and
colleagues (2008) added a behavioural intervention for
depression (BATD) to inpatient treatment for illicit drug
use (Lets Act!; N = 44) [31]. Those who received the Lets
Act! intervention had significantly greater improvements
in depression at post-treatment and 2-week follow-up
compared with standard care alone. A subsequent trial
compared Lets Act! with a time matched control treat-
ment (supportive counselling), and found that while
both groups showed a significant reduction in depressive
symptoms on completion of treatment, retention in drug
treatment was significantly greater in the behavioural
activation group [44]. No follow-up data was collected
beyond treatment completion. Another randomised
controlled trial (N = 68) involving adult smokers with
mildly elevated depressive symptoms and seeking smok-
ing cessation treatment, found that participants allocated
to ‘Behavioral Activation Treatment for Smoking (BATS)’,
which was adapted from BATD, reported greater smoking
abstinence, and a larger reduction in depressive symptoms
at 16- and 24-week follow-up, than those who received
standard smoking cessation treatment [47].
While the results of these trials are promising, and
suggest preliminary support for the feasibility, accep-
tability and efficacy of brief behavioural activation treat-
ment for improving mood and substance use outcomes,
further research is needed. BATD-R was initially deve-
loped for use in the United States (US) and its efficacy
has not been assessed in drug treatment services outside
the US, among substance users in outpatient drug and
alcohol treatment settings, or over long-term follow-up
(i.e., 12-months) in either residential or outpatient drug
treatment settings. The three clinical trials conducted to
date have also all used a group rather than individual
format.
Methods/design
Trial aims & hypotheses
The primary aim of the proposed trial is to determine
the efficacy of a modified version of BATD-R (Activate)
in reducing depressive symptoms among individuals
with SUDs who are currently undergoing Residential
Rehabilitation (RR) or Opioid Substitution Therapy
(OST). It is hypothesised that:
1. Participants who receive Activate will demonstrate
greater reductions in symptom severity for (i)
depression and (ii) substance dependence, 3- and
12-months post baseline, compared to those who
only receive treatment as usual.
2. Activate will be a feasible approach to treating
comorbid depression and substance dependence,
as measured by treatment retention and client
satisfaction.
The secondary aim of the trial is to investigate the
impact of other factors that may moderate or mediate
the Activate treatment response. Secondary outcome
measures will include those related directly to the the-
rapy (environmental reward, behavioural activation), and
those concerned with mental health (anxiety symptoms,
social phobia, borderline personality disorder, traumatic
events, rumination, distress tolerance, suicide history
and sleep).
Trial design
The Activate study is a parallel, single blind, superiority
randomised controlled trial. Participants will be randomly
assigned to receive either Activate (n = 100) or treatment
as usual (TAU; n = 100), stratified by treatment modality
(RR and OST). Treatment as usual is the comparator
group, as it is clinically important to determine whether
Activate adds any benefit in terms of improved depression
symptomatology and reduced dependence symptoms,
beyond that gained from usual care (i.e. RR or OST).
Separate randomisation schedules will be used for the two
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treatment modalities. To reduce the risk of bias, mini-
misation, a dynamic random allocation technique, will be
completed by someone independent of the research team
using Minim-Py [48]. Gender and depression severity have
been identified as significant prognostic factors and mini-
misation will ensure classification of participants with
respect to these variables. Depression severity will be
categorised according to BDI-II score, as mild (14–19),
moderate (20–28) or severe (29–63) [49]. Minimisation
has been shown to have both theoretical and practical
validity, in particular it is considered an effective rando-
misation tool in clinical trials of small to moderate sample
size (approximately, N = 200–400) with multiple prog-
nostic factors to be considered [50–52].
The National Health and Medical Research Council of
Australia (NHMRC) provided a project grant (#10444625)
enabling the Activate study to be conducted. The funding
period was initially February 2013 to December 2015, but
was extended to December 2016 to accommodate exten-
sion of the baseline recruitment phase. Ethics approval
was obtained from the University of New South Wales
Human Research Ethics Committee (HREC) (Ref No:
HC13155), and the Northern Sydney Local Health District
HREC (Ref No: HREC/12/HAWKE /404). A model of
the information and consent form used is available as
supplementary material (Additional file 1). The study has
been prospectively registered in the Australian and New
Zealand Clinical Trials Registry (ACTRN12613000876796,
7/08/13). Any changes to the trial protocol which may im-
pact the conduct of the study, the benefit to the patient or
patient safety, will require a formal amendment to the
protocol. Approval for such amendments will be sought
from the HRECs and the trial registry will be updated. See
Table 1 for the WHO Trial Registration Data Set. Add-
itional information regarding groups overseeing the trial,
insurance coverage, and authorship guidelines can be
found in the supplementary material (Additional file 1).
Sample size calculation
Power analysis on the primary outcome variables (i.e.,
severity of dependence and depressive symptoms) was
conducted using Power Analysis and Sample Size software
[53]. Based on previous research, including the longitu-
dinal study of treatment outcomes for heroin dependence
(ATOS; [20]), an exchangeable working correlation matrix
and a within-subject correlation of ρ1 = .60 for depen-
dence and ρ1 = .023 for depression was assumed. The
proposed final sample size of 160 will allow for the detec-
tion of clinically meaningful differences between the treat-
ment and control groups. Specifically, it will allow for the
detection of a time-averaged difference of 3 in severity of
substance dependence with a standard deviation of 5 (β =
99 % power; α = 0.05); a 15 % difference in the prevalence
of substance dependence (β = 96 % power; α = 0.05); a
difference of 5 in BDI-II scores with a standard deviation
of 15 (β = 81 % power; α = 0.05); and a 15 % difference in
the prevalence of major depression (β = 93 % power; α =
0.05). To allow for an expected attrition rate of 20 %, the
initial sample will be 200, with the aim of recruiting 50 %
of participants from RR and 50 % from OST.
Participants will be 18 years of age or older, literate in
English, willing to give locator information, and must
have been in RR for at least 1 week or OST for at least
3 months. RR clients must have used a substance (i.e.,
alcohol, methamphetamines, cannabis, cocaine, halluci-
nogens, illicit benzodiazepines, heroin or other opiates/
opioids) at least four times in the month prior to deto-
xing, and OST clients must have used a substance at
least four times in the past month. If alcohol is the only
substance used, individuals need to have consumed four
or more standard drinks on at least 4 days in the month
before detoxing/past month. The depression screening
criteria from the Composite International Diagnostic
Interview 3.0 (CIDI; [54, 55]) must be endorsed, indi-
cating that the individual has experienced symptoms of
depression that persisted for 2 weeks or longer in the
month before detoxing/past month, and these symptoms
must be ongoing. Depression symptom severity will be
assessed using the Patient Health Questionnaire (PHQ-9;
[56]), with a score in the mild to severe range (i.e., 5–27)
required to be eligible for the study.
Active suicidality, psychosis and organic or traumatic
brain injury will exclude an individual from entering the
study. Suicidality is assessed by the PHQ-9 during the
screening interview. Participants are asked “in the past
2 weeks/2-weeks before detox, have you been bothered
by thoughts that you would be better off dead.” If parti-
cipants indicate that they have been bothered by these
thoughts, the research officer then probes further, using
questions taken from the Suicide Assessment Kit screener
[57], to determine whether these thoughts are ongoing,
how long they have been having the thoughts, how intense
they are, how likely it is that they will act on these thoughts
in the near future, whether they have ever attempted
suicide previously, and if so, how recently. Individuals who
have attempted suicide in the past 6 months and for whom
nothing has changed (i.e., they have received no inter-
vention, or nothing has changed in their circumstances to
reduce their risk), will be excluded from the study, and
given a referral for appropriate support. If the thoughts are
intense or the participant deems it likely that they will act
on them in the near future, they are asked about any
current plans and prior attempts, and are referred to an
appropriate staff member at the treatment service for
ongoing support and management.
Suicidality is assessed further as part of the baseline
interview. The BDI-II and CIDI 3.0 both ask questions
about suicidal thoughts, with the CIDI also asking about
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Table 1 Trial registration data set as recommended by the World Health Organization (WHO)
Data category Information
Primary registry and trial identifying number Australian and New Zealand Clinical Trials registry, ACTRN12613000876796
Date of registration in primary registry 7 August, 2013
Secondary identifying numbers Universal Trial Number U1111-1142-2213
Source(s) of monetary or material support National Health and Medical Research Council
Primary sponsor National Drug & Alcohol Research Centre, University of New South Wales, Sydney, NSW 2052
Contact for public queries Joanne Ross (j.ross@unsw.edu.au)
Contact for scientific queries Joanne Ross National Drug & Alcohol Research Centre, UNSW, Sydney, Australia
Public title Treatment for depression among people with substance use disorder: The Activate Study
Scientific title The efficacy of behavioural activation therapy for co-occurring depression and
substance use disorder: The Activate Study
Countries of recruitment Australia
Health condition(s) or problem(s) studied Depression and Substance Use Disorder
Intervention(s) The intervention is Behavioral Activation Treatment for Depression (BATD-R), modified
for use in outpatient and in-patient drug and alcohol treatment settings (Activate).
Comparator: Treatment as usual i.e. Residential Rehabilitation (RR) or
Opioid Substitution Treatment (OST).
Key inclusion and exclusion criteria Inclusion criteria:
a) 18 years of age or older
b) Literate in English
c) Willing to give locator information
d) Entered RR within the last month or in OST for at least 3 months
e) Endorse CIDI 3.0 depression screening criteria
f) Score at least in the mild range on PHQ-9




c) Organic or traumatic brain injury
d) Not living in the greater Sydney metropolitan area
e) Not living in the community in the month prior to baseline
Study type Interventional. Allocation: randomised; intervention model: parallel assignment;
Masking: the research officers assessing outcomes are blind to the allocation
Primary purpose: Treatment
Date of first enrolment 12/08/2013
Target sample size 200
Recruitment status Recruitment completed. Analysis ongoing.
Primary outcome(s) 1) Depression Severity
- Beck Depression Inventory (BDI-II) score
- Composite International Diagnostic Interview 3.0 (CIDI) assessment of Major Depression.
2) Substance Use Disorder
- CIDI assessment of substance use disorder
- Severity of dependence scale (SDS)
Key secondary outcomes 1) Treatment feasibility as assessed by treatment retention and client satisfaction
(assessed using the Client Satisfaction Questionnaire on completion of the Activate intervention)
2) Factors that influence the efficacy of the modified BATD-R
(Activate) including client and treatment characteristics (assessed at baseline, 3 and 12 months).
Date and version identifier: Issue date: 17 Feb 2016
Protocol amendment number: 01 Authors: KP, JR
Revision chronology:
00, 7 August, 2013 Original
01, 17 February, 2016 Amendment 01.:
Two exclusion criteria, i.e. d) not living in the greater Sydney metropolitan area and e) not living in the community in the month prior to baseline, were added, as
omitted from the original list
Actual date that the first participant entered the study was added (12.08.13)
Date of last participant enrolment was changed from 3.12.14 to 26.02.15. The baseline recruitment phase was extended due to delays with ethics and to help
boost recruitment
List of recruitment sites was updated
File updated to indicate that Ethics Approval was obtained from Northern Sydney Local Health District HREC on 4 December 2013
Ross et al. BMC Psychiatry  (2016) 16:221 Page 5 of 14
plans and attempts [49, 55]. Additional questions about
the lifetime number of suicide attempts and recency of
the last attempt are also asked. In situations where
suicidality is indicated, the research officer uses the add-
itional probing questions described above to assess their
current risk, and to determine whether there is a need for
exclusion from the study and referral for additional sup-
port. It is possible for a person with a current plan and
thoughts of suicide to be recruited to the study provided
the risk is not deemed imminent, and the treatment
service is made aware of the suicidal thoughts and plan.
As part of the screening questionnaire, potential parti-
cipants are asked whether they have ever been diagnosed
with bipolar, mania, or schizophrenia. If the response is
yes, (or if the individual reports being prescribed antipsy-
chotics during the baseline interview), the project psych-
ologist will meet briefly with them and ask them whether
they ever see or hear things that other people cannot see
or hear, whether the hallucinations are believed to be drug
induced, whether the hallucinations are current, and how
these are managed. These individuals are also asked about
having unusual thoughts or beliefs. The psychologist then
makes a clinical decision about their eligibility for the
study. Self-report of having received a diagnosis of trau-
matic brain injury, as ascertained during the screening
interview, is also a reason for exclusion.
Exclusion from the study in all of the above cases is
based on the individual’s inability to effectively engage
with, and thus benefit from, the type of intervention of-
fered. Decisions to exclude on the basis of suicidality,
psychosis or traumatic brain injury will all be made in
consultation with the project coordinator and/or a project
psychologist prior to randomisation. Alternate referral for
treatment will be provided where necessary. Additionally,
for reasons of feasibility in providing the Activate inter-
vention and contacting participants for follow-up, clients
will be excluded if they do not live in the Greater Sydney
Metropolitan, Central Coast or Hunter New England
regions. To ensure that participants have been at liberty to
use substances in the month prior to detox or past month,
individuals not living in the community (e.g., incarcerated)
during that period will be excluded.
Study procedure
Sample site recruitment
Participants will be recruited from RR services and OST
clinics in greater Sydney metropolitan area, the Central
Coast, and Hunter New England Health regions. Man-
agement staff will be contacted by the project coordinator
to determine their initial interest in being involved. A
letter outlining the purpose of the trial, and what will be
required of the agency should they choose to participate,
will be sent to the services. On confirmation of intent to
participate, the research team will meet with the staff to
discuss logistics, and recruitment of study participants
will commence.
Screening
Staff in the RR and OST services will inform clients that
the University of New South Wales is conducting a study
examining mood and substance use. They will direct those
interested in hearing about the study and being screened
for eligibility, to one of the project’s research officers who
will be on-site to conduct the screening to help maximise
recruitment. Informed written consent will then be sought
by the research officers from eligible clients interested in
participating, locator information to facilitate follow-up
will be collected, and the baseline interview conducted.
The research officers (honours graduates in psychology)
have been trained in the assessment interview by the
investigators (MT, JR and KM). Participants will be
informed that they are free to withdraw from the study at
any stage. Recruitment will occur in ten treatment services
over a period of 18 months. The locations of the treatment
services are listed in the Australian and New Zealand
Clinical Trials registry.
Assessment occasions
The structured baseline interview will be administered by
the research officers, followed by randomisation of partici-
pants to one of two groups; (1) TAU, or (2) Activate plus
TAU (Fig. 1). The allocation sequence will be computer-
generated by someone independent of the Activate team.
The project coordinator will then inform the psychologist
about the allocation, and they will notify the study partici-
pant. Follow-up interviews for the Activate and TAU
groups will parallel each other, conducted at 3-months
and 12-months post-baseline. Primary and secondary
outcome measures will be assessed at all three assessment
occasions, with the exception of client satisfaction, which
will be assessed on completion or cessation of the Activate
intervention. Follow-up interviews will be administered by
the project’s research officers who will be blind to group
allocation. The baseline and follow-up interviews are
estimated to take 60–90 min to complete. Participants will
be reimbursed AU$30 per interview for out of pocket
expenses.
Locator information
A locator form will be used to record participant infor-
mation that may be used to facilitate follow-up. This
information will be collected at baseline and updated on
both follow-up occasions. Consent to the study also
provides permission for researchers to locate the parti-
cipant by various means, such as social media, telephone
directories, court lists, electoral rolls, and treatment ser-
vices. These methods are based on those used in ATOS
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which achieved follow-up rates of 89, 80, 76, and 70 % at
3-, 12-, 24-, and 36-month follow-ups respectively [58].
Data management
To maintain confidentiality of participant data, all parti-
cipant information will be stored in locked filling cabinets
at the National Drug and Alcohol Research Centre, with
access restricted to the research team. All records that
contain names or other personal identifiers (such as
locator forms and consent forms), will be stored separately
from questionnaires, which will be identified by a parti-
cipant identification number. All local databases will be
secured with password protected access systems. Data
entry will be conducted by the research officers. To
maximise accuracy and consistency of data entry, a data
dictionary will be used to define the variables and specify
how they are to be coded. To promote data quality value
range checks and consistency checks will be performed.
Measures
Baseline and follow-up interviews
The baseline and follow-up interviews will examine demo-
graphics, drug use history, treatment history (for substance
use and depression), and will use validated instruments to
assess a) the primary treatment outcomes of depression
and substance dependence, and b) secondary treatment
outcomes related to the therapy and mental health. Demo-
graphic measures will include age, gender, level of educa-
tion, employment status, main source of income, marital
status, living arrangements, and prison history. A drug use
history (including age of first use, and the number of days
used in the last 30 and 90 days), will be obtained for
heroin, other opiates, methamphetamine, cocaine, halluci-
nogens, antidepressants, benzodiazepines, alcohol, canna-
bis, inhalants and tobacco. Prescription drug use will also
be recorded. Drug treatment and depression treatment
history will assess current treatment(s), the age at which
they first sought treatment, number of times they have
commenced treatment, and the recency of these treat-
ments. Information will also be obtained on the partici-
pants’ history of suicide, self-harm, and occasions where
they lost consciousness as the result of a head injury.
Primary outcome measures
Depression: The severity of depression symptoms in the
past 2 weeks will be assessed using the 21-item Beck
Fig. 1 Flow Diagram of Trial Progression
Ross et al. BMC Psychiatry  (2016) 16:221 Page 7 of 14
Depression Inventory (BDI-II; [49]). Each item comprises
a list of four statements arranged in increasing severity
about a particular symptom of depression. Scores range
from 0 to 63, with higher total scores indicating more
severe depressive symptoms. Depression can then be
interpreted as minimal (0–13), mild (14–19), moderate
(20–28), or severe (≥29). The BDI-II has been widely used
in both clinical and non-clinical studies, has shown good
test-retest reliability (Pearson’s r = .73-.96), and high
internal consistency (Chronbach’s α = .83-.96) [59]. A past
month diagnosis of major depression will be ascertained
by completing the CIDI 3.0 depression section, modified
to assess the presence of symptoms in the past month
[54, 55]. The CIDI 3.0 major depression module has
been found to have moderate concordance with the
Structured Clinical Interview for DSM (SCID) (area under
the receiver operator curve; AUC = 0.75) [60].
Substance Dependence: Psychological components of
dependence will be measured using the Severity of
Dependence Scale (SDS; [61]). Each of the 5 items is
scored on a 4-point scale, ranging from 0 to 3. A total
score is obtained, with higher scores indicating a higher
level of dependence. The inter-item reliability has been
demonstrated across five drug using samples, with
Cronbach’s alpha values ranging between 0.8 and 0.9
[61]. A diagnosis of substance dependence will be esta-
blished using the CIDI 3.0, with the number of depen-
dence criteria endorsed (0–7) being used as an indicator
of severity [54]. The CIDI 3.0 substance use disorder
module has been found to have moderate concordance
with the SCID (Alcohol dependence, AUC = 0.72; Drug
dependence, AUC = 0.62) [60].
Problematic alcohol use will be screened for using the
4-item CAGE questionnaire [62]. Scores range from 0 to
4, with scores greater than or equal to 2 considered to
be clinically significant. The CAGE has demonstrated
high test-retest reliability (r = 0.80–0.95), and adequate
correlations (r = 0.48–0.70) with other screening instru-
ments such as the Alcohol Use Disorders Identification
Test (AUDIT) and Short Michigan Alcohol Screening
Test (SMAST) [63].
Symptom monitoring and secondary outcome measures
The Patient Health Questionnaire-9 (PHQ-9) will be
used in the initial screening interview, and then by the-
rapists to monitor depressive symptoms among the inter-
vention group [56]. The PHQ-9 is a nine-item screener
for major depression and a measure of depression seve-
rity, which assesses the presence of each of the nine
DSM-IV criteria for major depression in the preceding
2 weeks. Scores range from 0 to 27, as each of the nine
items can be scored from ‘0’ (not at all) to ‘3’ (nearly every
day) [56]. Major depression is indicated if 5 or more of the
9 depressive symptom criteria have been present at least
“more than half the days” in the past 2 weeks, and 1 of the
symptoms is depressed mood or anhedonia. The PHQ-9
has demonstrated excellent internal reliability (Chronbach’s
α = 0.86–0.89), and test-retest reliability (r = 0.84) [56].
Criterion validity has been demonstrated in a sample of
580 primary care patients who were independently re-
interviewed by a mental health professional. Receiver
Operator Curve (ROC) analysis showed that the area
under the curve for the PHQ-9 in diagnosing major
depression was 0.95, suggesting that it discriminates well
between persons with and without major depression [56].
Client satisfaction will be assessed after completion of
Activate therapy using the Client Satisfaction Question-
naire, an 8-item scale designed to measure and assess
client satisfaction with health and human services (CSQ-
8; [64]). The CSQ-8 elicits the client’s perspective on the
value of services received. Responses are given on a
4-point Likert scale. Scores range from 8 to 32, with
higher scores indicating greater satisfaction. The
CSQ-8 has demonstrated excellent reliability and internal
consistency (Cronbach’s alpha 0.92 to 0.93) [64]. Secon-
dary outcome measures, including those associated with
behavioural activation therapy and mental health will be
assessed at baseline, 3- and 12-month follow-up (Table 2).
Intervention
The trial will use a modified version of the BATD-R
manual (Activate), which involves 10 individual, weekly
60-min sessions, with a psychologist from the research
team. The 10-session format allows for the inclusion of
topics deemed important for the target population, and
there is evidence that clinically significant improvements
in depression symptoms can be achieved within this
period [45]. The BATD-R manual was modified to include
psychoeducation about the relationship between substance
use and depression. To assist in establishing treatment
goals in relation to their substance use, some motivational
interviewing techniques were incorporated. Namely, this
involved asking questions to elicit change talk, such as,
‘What would you like to be different about your current
situation?’ Other additions include the provision of a list of
behavioural techniques for managing craving [65], and a
simple breathing exercise. Given the high levels of psy-
chiatric comorbidity among substance users in drug treat-
ment [66, 67], self-soothing and grounding techniques
have been included for managing emotional distress, and
defusion exercises for the management of unhelpful
thoughts. Participants may choose to withdraw from the
intervention at any time, but will still be contacted for
follow-up assessment, unless they have withdrawn from
the study.
To encourage treatment attendance participants in
Activate will receive a reminder call the day prior to each
session to confirm their appointment for the following day
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and appointment times will be highly flexible throughout
the treatment program, with the option to reschedule
appointments if required. Therapists will keep logs of
clients’ attendance at sessions.
The use of project therapists, as opposed to existing
clinicians within treatment agencies, has been chosen to
minimise the risk of contamination of the control group.
In order to avoid the outcome of Activate being attri-
buted to a single therapist bias, two clinical psycholo-
gists will be employed. Both psychologists will receive
extensive training in treatment delivery, provided by the
lead developer of BATD-R, Carl Lejuez, and will be super-
vised by a senior clinical psychologist with experience in
the treatment of depression and substance use. The Acti-
vate treatment manual will be taken into each session by
the therapist to ensure all proposed areas are covered. The
therapist will also complete a session checklist, with any
deviations from the therapy manual recorded in the
clinical notes kept for each session. Weekly clinical
supervision will be held with the chief investigators,
where session checklists will be monitored. In addition, all
treatment sessions will be audio-recorded to allow for
assessment of treatment fidelity.
Overview of treatment
Session One covers the procedural aspects of treatment
such as conditions of confidentiality, the recording of
sessions, suicide risk assessment as well as guidelines for
treatment and emphasising the importance of attending
each weekly session. Session One also provides psycho-
education about the role of substance use in depression,
explores the participant’s current situation and their ideal
life, reviews the treatment rationale as well as introducing
behaviour monitoring. The first session introduces the
weekly homework assignment which is repeated each
subsequent session. This involves the monitoring of acti-
vities on an hourly basis with the participant also provi-
ding ratings on the enjoyment and importance of each
activity on a numerical scale from 1 to 10, as well as a
rating of their overall daily mood from 1 to 10 (1 being
low and 10 being high).
Table 2 Schedule of assessments
Domain Measure Screening Baseline
Pre-allocation
3 month follow-up 12 month
Follow-up
Eligibility
Depression symptoms Patient Health Questionnaire (PHQ-9) [56] + − − −
Depression screener CIDI 3.0 Depression screener questions [54, 55] + − − −
Primary outcome measures
Substance dependence CIDI 3.0 Substance dependence
(past month DSM-IV TR) [54]









Depression CIDI 3.0 Major depression
(past month DSM-IV TR) [54, 55]










Behavioural activation Behavioural Activation for Depression Scale Short Form
(BADS-SF; [70])
− + + +
Anxiety Beck Anxiety Inventory (BAI; [71]) − + + +
Social phobia CIDI 3.0 Social Phobia (past month DSM-IV-TR) [54]









Traumatic events & trauma
symptoms
PTSD trauma checklist from the CIDI 3.0 [54] and the
Post-Traumatic Stress Disorder Checklist – Civilian Version
(PCL-C; [74])
- + + +
Borderline Personality Disorder International Personality Disorders Examination (IPDE;
[75])
− + + +
Environmental Reward Environmental Rewards Observation Scale (EROS; [76]) − + + +
Rumination Perseverative Thinking Questionnaire (PTQ; [77, 78])
and Ruminative Response Scale (RRS; [79])
− + + +
Distress Tolerance Distress Tolerance Scale (DTS; [80]) − + + +
Sleep disturbance Pittsburgh Sleep Quality Index (PSQI; [81]) − + + +
Chronic physical conditions As outlined by the Australian National Health
Priority Area [82, 83]
− + + +
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Session Two begins with the revision of substance use,
depression symptoms and suicide risk, followed by a
detailed review of the daily monitoring forms completed
that week. This review occurs in all subsequent sessions.
Enjoyment and importance ratings are considered for
each activity and participants explore any difficulties that
they had completing monitoring forms. The treatment
rationale is reviewed prior to introducing the concept of
life areas (relationships; education/career; recreation/
interests; mind/body/spirituality and daily responsibilities).
The majority of the session focuses on exploring the
participant’s values within each of the life areas and gene-
rating activities that are associated with each life area.
Finally, participants are introduced to a list of behavioural
activities to assist in coping with cravings for substances.
These include using delay and distract techniques, man-
aging hunger and thirst, using controlled breathing tech-
niques, imagery exercises such as “urge surfing”, seeking
social support, and using positive self-talk.
During the third session, participants continue to gene-
rate activities that are value based for each life area. They
then choose fifteen of these activities and rank them in
order from easiest to hardest taking into account the level
of expected enjoyment and importance of each activity.
The participant is encouraged to include some activities
that they are already engaged in. Session Three concludes
with the introduction of the two brief behavioural tech-
niques for managing emotional distress, these include a
self-soothing exercise (where the client is asked to use
their five senses to create more soothing moments in
their day), and a breathing exercise where participants
slow their breathing and think of the word “relax” when
exhaling.
In Session Four participants revisit the activity list from
the previous session and choose activities to schedule into
their monitoring forms for the upcoming week. They
progress from easier to harder activities and have the
opportunity to reassess the order of activities throughout
sessions. The process of selecting activities from their list
occurs each session until the end of treatment. Partici-
pants are encouraged to choose between one and three
new activities each week from a variety of different life
areas. Session four ends with the introduction of a defu-
sion exercise (e.g. using repetition or singing the thought).
Session Five introduces the concept of contracts with
significant others. Participants are encouraged to select
an activity that they have found difficult to complete and
then select three friends or family members who may be
able to assist them to complete this activity. The aim is
to increase social support and increase enjoyment in
completing activities. Sessions Six to Ten reinforce mate-
rial previously introduced with a focus on activity selec-
tion and monitoring. In Session Six a simple grounding
exercise is introduced at the end of the session (notice five
things you can see, hear and feel). Similarly, at the end of
Session Eight a basic mindfulness exercise is introduced
for participants to practice.
Session Ten concludes treatment with a list of skills
achieved and an opportunity to explore the management
of potential setbacks. Throughout treatment, partici-
pants are encouraged to recognise patterns of depressed
behaviour and the way in which engaging in enjoyable
and important activities may impact their overall mood.
Prior to each session participants will complete the
PHQ-9 [56] and be asked how many days they have used
substances (alcohol, cannabis, benzodiazepines, heroin,
other opiates, methamphetamine, and ‘other’) in the past
week. This will enable therapists to monitor depressive
symptoms and substance use throughout treatment, and
help to identify unfavourable changes in symptoms. If
concerned for the safety and wellbeing of the participant,
the therapist will consult with the project coordinator,
additional support services will be offered to the parti-
cipant, and it will be determined whether or not ongoing
therapy is appropriate for them. Although unlikely, any
adverse events attributed to the intervention will be
reported the HRECs. The participant information sheet
also instructs participants to contact the project coor-
dinator if they experience “significant distress as part of
this study” and provides contact details for the ethics
secretariat should they which to make a complaint about
the conduct of the study.
Treatment as usual
The control group will receive the model of care provided
in accordance with standard practice at participating RR
and OST services, and will be delivered by agency staff. In
addition to standard drug and alcohol treatment, clients
in RR may receive additional treatment from case workers
or in-house psychologists. Similarly, in addition to metha-
done or buprenorphine maintenance for managing heroin
dependence, OST clients may also receive counselling for
depressive symptoms, antidepressant medication where
appropriate, and referral to mental health services when
required. All treatment for depression received as a part
of TAU will be recorded in participant interviews. These
will be controlled for in comparative analysis of treatment
outcomes.
Statistical analysis
The proportion of screened clients entering the study
will be determined. T-tests and chi-square analyses will
be conducted to determine if those who did not enrol in
the study were systematically different from those who
did. T-tests and chi-square analyses will also be conducted
to determine if there were any significant differences
between the treatment and control groups at baseline. For
outcome analyses, both intention-to-treat (i.e. analyses
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include all randomised participants, regardless of protocol
adherence) and per-protocol analyses (i.e. where the inter-
vention group only includes participants who received at
least one session) will be conducted. Categorical and con-
tinuous measures of outcome will be examined using
mixed or marginal longitudinal models.
To evaluate treatment fidelity, 10 % of each therapist’s
sessions will be rated for compliance with the treatment
manual. Interim descriptive analyses will take place at
each assessment stage (including the baseline assessment),
to assist with the monitoring of data collection and data
entry. These analyses will be conducted by the research
officers, who will not have access to the treatment allo-
cation variable. Final stage analyses will be carried out
after completion of the 12 month follow-up.
Dissemination of results
The research team intend presenting the findings of this
trial at professional seminars, national and international
conferences, and in manuscripts submitted for publi-
cation in peer-reviewed journals. Results will also be
reported to the UNSW and Northern Sydney Local
Health District HRECs. Only aggregated group data will
be reported and no individuals will be identified.
Discussion
This protocol presents the design of the Activate study,
a randomised controlled trial, which seeks to evaluate
the efficacy of a modified version of BATD-R (Activate)
among individuals in treatment for SUDs. The primary
aim of the study is to investigate the efficacy of the Acti-
vate intervention in comparison to treatment as usual,
in reducing symptoms of depression and substance de-
pendence. For the Activate intervention group, treatment
retention, client compliance, and client satisfaction will
be assessed. The secondary aim of the study is to examine
whether other factors, including those associated with
therapy (environmental reward, behavioural activation),
and those concerned with mental health (anxiety and
social phobia, borderline personality disorder, traumatic
events, rumination, distress tolerance, and sleep), impact
upon the Activate treatment response.
Strengths and limitations
A strength of the Activate study is that it is the first
randomised controlled trial to evaluate the efficacy of
behavioural activation therapy for depression among
individuals in both inpatient and outpatient substance
abuse treatment settings, and in an individual format.
Follow-up assessments will occur at 3- and 12-months
post-baseline in both the Activate intervention group
and the control (TAU) group, which will provide an
opportunity to evaluate the long-term effects of Acti-
vate among this population for the first time. Primary
outcomes of severity of depression and dependence will
be assessed by research officers who will be blind to treat-
ment allocation, using validated measures. The incorpo-
ration of some motivational interviewing techniques, a
brief relaxation strategy, and psychoeducation about the
role of substance use in depression targets the inter-
vention more specifically for substance users. Defusion
exercises, self-soothing and grounding techniques have
been included to equip participants with skills for man-
aging rumination and emotional distress, which are preva-
lent among this group [68], so they can attend to the
BATD-R protocol more fully.
One limitation of the Activate study is excluding indi-
viduals who have active suicidality, self-harm or psy-
chosis, and those who report organic or traumatic brain
injury. This may be considered to reduce the genera-
lisability of results to a real world sample. However, these
exclusion criteria were based on the individual’s likely
inability to effectively engage with, and thus benefit from
the type of intervention offered. A potential challenge for
the study will be retaining participants, as individuals with
SUDs are traditionally very difficult to follow-up. To maxi-
mise follow-up rates, research officers will build good
rapport with participants, obtain detailed contact infor-
mation to help with locating participants, reinforce to
participants the importance of conducting follow-ups, and
financially compensate participants for the time required
to complete the interviews (AU$30). These methods have
been utilised in previous studies among substance users,
which achieved commendable 12-month follow-up rates
of around 80 % [20, 69].
Conclusion
Integrated treatment is recommended in people with
psychiatric illness comorbid with substance use problems.
Yet, there are currently few evidence based treatment
options for co-occurring depression and SUD. BATD-R is
a manualised treatment that has shown promise among
drug and alcohol residential rehabilitation clients [31, 44]
and among psychiatric inpatients [46], but larger, longer
term trials are needed to broaden the BATD-R evidence
base. The Activate study will be one of the few rando-
mised controlled trials of psychosocial treatments for this
comorbidity to be conducted internationally. The findings
are likely to contribute significantly to understanding the
types of programs that are effective in treating this
comorbidity.
Additional files
Additional file 1 “Activate participant information and consent
form”—This file provides a model of the information and consent form
used in the trial (DOC 293 kb)
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Additional file 2 “Groups overseeing the trial, insurance coverage
provided by UNSW, and authorship guidelines”—This document outlines
the role and composition of groups overseeing the trial, the insurance
coverage provided by UNSW and the authorship guidelines that will be
used for papers based on trial data (DOCX 16 kb)
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